Freshfields advises Roivant on sale of Telavant to Roche for $7.1 billion in cash and a near-term milestone payment of $150 million in cash

[ad_1] News 25 October 2023 Freshfields is advising Roivant Sciences Ltd. (Nasdaq: ROIV) on the sale of Telavant, a Roivant company owned by Roivant and Pfizer, to Roche for…

Roche agrees $7.1bn deal for Telavant to boost drug pipeline

[ad_1] Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Roche plans to buy immunology company Telavant from Roivant…